WebCompass Pathways is a mental-health-focused pharmaceutical company that is developing psilocybin-based treatments for patients suffering from depression. Founded in 2016, the company has developed a proprietary form of psilocybin called COMP360 for cases of major depressive disorder that resist more traditional treatment options. WebApr 12, 2024 · COMPASS Pathways isn't enormous, but it's not particularly small either. ... It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your ...
Buy COMPASS Pathways PLC stock (CMPS) Stash
WebCOMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Its focus is on improving the lives of those who are... WebDec 26, 2024 · Despite having an IPO just three months ago, Compass Pathways ( CMPS 5.84%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 … magick image converter
CMPS: COMPASS Pathways - Brokerage Recommendations Chart - Zacks.com
WebBuy COMPASS Pathways Shares. Compass Pathways Plc (CMPS) is a publicly traded medical care facilities business based in the US. In the week up to 24 February COMPASS Pathways shares plunged 8.41% to a closing position of $8.6. Over the last 12 months, COMPASS Pathways's share price has fallen by 33.55% from $12.16. WebCOMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa. Multi-centre, double-blind randomised controlled phase 2 trial will investigate the … WebNov 12, 2024 · Compass Pathways stock is in an IPO base with a 47.39 buy point. The stock has a 41 Composite Rating. After losing money, shares have a worst-possible EPS Rating of 1. Compass Pathways... magickimage quality